Samraat S. Raha - 09 Mar 2026 Form 4 Insider Report for MYRIAD GENETICS INC (MYGN)

Reporting relationship: President and CEO, Director
Issuer ticker: MYGN
Reported as of: 09 Mar 2026
Net transaction value: +$199,844
SEC form: 4
Accepted by SEC: 09 Mar 2026, 19:03:13 UTC
Prior SEC filing: 12 Dec 2025
Next SEC filing: 16 Mar 2026
Source filing: View source filing
Reporting owner signature: By: Justin Hunter For: Samraat S. Raha

Key filing fact

Samraat S. Raha filed Form 4 for MYRIAD GENETICS INC (MYGN) on 09 Mar 2026.

Key facts

This page summarizes Samraat S. Raha's Form 4 filing for MYRIAD GENETICS INC (MYGN).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 09 Mar 2026, 19:03.

Change

Previous filing in this sequence was filed on 12 Dec 2025.
Current net transaction value: +$199,844.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001738340 Primary reporting owner

Raha Samraat S.

Relationship: President and CEO, Director
Address: 322 NORTH 2200 WEST, SALT LAKE CITY
Signature: By: Justin Hunter For: Samraat S. Raha
Signature date: 09 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MYGN transaction

Common Stock

Purchase

Transaction value: $199,844
Shares: +40,000
Change %: +8.8%
Price: $5.00
Shares after: 493,104
Date: 09 Mar 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.97 to $5.00, inclusive. The reporting person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.